Mezgebe Berhe

1.6k total citations · 1 hit paper
26 papers, 403 citations indexed

About

Mezgebe Berhe is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Mezgebe Berhe has authored 26 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 9 papers in Virology and 8 papers in Epidemiology. Recurrent topics in Mezgebe Berhe's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and Hepatitis C virus research (6 papers). Mezgebe Berhe is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and Hepatitis C virus research (6 papers). Mezgebe Berhe collaborates with scholars based in United States, United Kingdom and France. Mezgebe Berhe's co-authors include Michael B. Edmond, Gonzalo Bearman, Martin S. Rhee, Peter Ruane, Jared M. Baeten, Hadas Dvory‐Sobol, Edwin DeJesus, Hui Wang, Sorana Segal‐Maurer and Robert H. Hyland and has published in prestigious journals such as New England Journal of Medicine, AIDS and Medicine.

In The Last Decade

Mezgebe Berhe

22 papers receiving 386 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Sorana Segal‐Maurer, Edwin DeJesus et al. profile →

Peers

Countries citing papers authored by Mezgebe Berhe

Since Specialization

Citations

This map shows the geographic impact of Mezgebe Berhe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mezgebe Berhe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mezgebe Berhe more than expected).

Fields of papers citing papers by Mezgebe Berhe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mezgebe Berhe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mezgebe Berhe. The network helps show where Mezgebe Berhe may publish in the future.

Co-authorship network of co-authors of Mezgebe Berhe

This figure shows the co-authorship network connecting the top 25 collaborators of Mezgebe Berhe. A scholar is included among the top collaborators of Mezgebe Berhe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mezgebe Berhe. Mezgebe Berhe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV 2025 ·AIDS ·Debbie Hagins, Mezgebe Berhe, Gordon Crofoot, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E. Sanchez, Anita Scribner, Paul Benson, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Samir K. Gupta	0
2	Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study 2025 ·Medicine ·Indira Brar, Peter Ruane, Mezgebe Berhe, Cynthia Brinson, Paul Benson, Keith Henry, Hui Liu, Kristen Andreatta, Jason T. Hindman, Moti Ramgopal	0
3	577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir 2025 ·Open Forum Infectious Diseases ·Amy E. Colson, (unknown), Peter Ruane, Moti Ramgopal, Alexandra W. Dretler, Ronald Nahass, Gary Sinclair, Mezgebe Berhe, (unknown), Shanyu Liu, Stephanie O. Klopfer, Sharline Madera, Hadas Dvory‐Sobol, Martin S. Rhee, Elizabeth G. Rhee, Jared M. Baeten, Joseph J. Eron	2
4	Activité antivirale, tolérance et pharmacocinétique du GS-1720, un nouvel INI oral hebdomadaire 2024 ·(unknown), Mezgebe Berhe, (unknown), Jacob Lalezari, Godson Oguchi, Gary Sinclair, Fudi Wang, (unknown), (unknown), (unknown)	1
5	Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks 2023 ·Open Forum Infectious Diseases ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, (unknown), Moti Ramgopal, Dushyantha Jayaweera, Peter A. Leone, Jessica Matthews, (unknown), Mark Underwood, Konstantinos Angelis, Brian Wynne, (unknown), Christopher Nguyen, Jean van Wyk, Andrew Zolopa	11
6	1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results 2023 ·Open Forum Infectious Diseases ·Onyema Ogbuagu, Edwin DeJesus, Mezgebe Berhe, Gary Richmond, Peter Ruane, Gary Sinclair, Moti Ramgopal, William E. Sanchez, (unknown), Nicolas Margot, Hui Wang, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Sorana Segal‐Maurer	4
7	Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir 2022 ·Baylor University Medical Center Proceedings ·(unknown), Mezgebe Berhe, Uriel Sandkovsky	0
8	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 2022 ·The Lancet HIV ·Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, (unknown), Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig	65
9	1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials 2022 ·Open Forum Infectious Diseases ·Moti Ramgopal, (unknown), Axel Baumgarten, Mezgebe Berhe, Anton Pozniak, Chloe Orkin, Juan Tiraboschi, Debbie Hagins, Hailin Huang, (unknown), (unknown), Jason T. Hindman, (unknown), Jared M. Baeten, Olayemi Osiyemi	3
10	Impact of antimicrobial selection for prophylaxis of left ventricular assist device surgical infections 2021 ·Journal of Cardiac Surgery ·(unknown), (unknown), (unknown), (unknown), Joost Felius, Mezgebe Berhe, Dan M. Meyer	4
11	75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study 2021 ·Open Forum Infectious Diseases ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, (unknown), Moti Ramgopal, Dushyantha Jayaweera, Peter A. Leone, Jessica Matthews, (unknown), Mark Underwood, (unknown), Brian Wynne, (unknown), Christopher Nguyen, (unknown), Andrew Zolopa	1
12	Brucella, a bacterium with multiple ways of causing infection 2020 ·Baylor University Medical Center Proceedings ·(unknown), Mezgebe Berhe	3
13	1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine 2020 ·Open Forum Infectious Diseases ·Indira Brar, Peter Ruane, Douglas Ward, Jean‐Michel Molina, Anthony Mills, Mezgebe Berhe, Cynthia Brinson, (unknown), Paul Benson, Keith Henry, Hailin Huang, Kristen Andreatta, Hal Martin	3
14	The dynamic treatment of SARS-CoV-2 disease 2020 ·Baylor University Medical Center Proceedings ·Uriel Sandkovsky, (unknown), (unknown), Ariel Modrykamien, Mezgebe Berhe	2
15	Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems 2019 ·Baylor University Medical Center Proceedings ·(unknown), (unknown), Hoa L. Nguyen, Mezgebe Berhe	9
16	661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311) 2019 ·Open Forum Infectious Diseases ·Brinda Emu, Edwin DeJesus, Mezgebe Berhe, Jason Leider, Catherine Creticos, (unknown), Zvi R. Cohen	6
17	Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin 2018 ·Baylor University Medical Center Proceedings ·Amy Carr, (unknown), Mezgebe Berhe, Hoa L. Nguyen	0
18	Tularemia Presenting as Pulmonary Nodules in an Immunocompromised Patient 2017 ·Baylor University Medical Center Proceedings ·(unknown), Mohammad Kazem Fallahzadeh, Mezgebe Berhe	5
19	Measurement and feedback of infection control process measures in the intensive care unit: Impact on compliance 2006 ·American Journal of Infection Control ·Mezgebe Berhe, Michael B. Edmond, Gonzalo Bearman	39
20	Practices and an assessment of health care workers' perceptions of compliance with infection control knowledge of nosocomial infections 2005 ·American Journal of Infection Control ·Mezgebe Berhe, Michael B. Edmond, Gonzalo Bearman	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact